Immuneering Corporation — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Immuneering is a clinical-stage oncology company with no approved products; it is developing IMM-1-104 and IMM-6-415 for RAS- and RAS/RAF-mutant solid tumors.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Research and development expense | $11.20 million | $10.21 million |
| General and administrative expense | $4.12 million | $4.46 million |
| Total operating expenses | $15.33 million | $14.68 million |
| Net loss | $14.31 million | $13.60 million |
| Net loss per share, basic and diluted | $0.49 | $0.51 |
| Net cash used in operating activities | $15.49 million | $14.42 million |
At March 31, 2024, cash and cash equivalents were $66.29 million and marketable securities were $4.99 million, totaling $71.28 million. Total current assets were $74.45 million; current liabilities were $5.18 million. The company reported $4.38 million of lease liabilities, including current and long-term portions, and no other borrowings are shown on the balance sheet. Accumulated deficit was $177.57 million. No operating margin is meaningful given the absence of reported revenue.
Cash and cash equivalents increased by $6.88 million during the quarter, as $21.43 million of marketable securities matured and provided investing cash flow, offsetting operating cash use. Financing activities provided $0.98 million, mainly from option exercises and the employee stock purchase plan. These cash-flow movements include transfers from securities to cash and should not be read as a reduction in underlying cash consumption.
Material changes versus prior comparable period
- Net loss increased by $0.70 million, or 5.2%; total operating expenses rose 4.4%.
- R&D expense increased $0.99 million, driven mainly by IMM-1-104 and IMM-6-415 development; spending on earlier-stage programs declined.
- G&A expense decreased $0.35 million, primarily due to lower professional fees and employee-related costs, partly offset by higher stock-based compensation.
- Operating cash use increased by approximately $1.07 million. The reported per-share loss improved to $0.49 from $0.51, while weighted-average shares increased to 29.37 million from 26.44 million.
- Cash, cash equivalents and marketable securities together declined from $85.67 million at December 31, 2023 to $71.28 million at March 31, 2024, mainly reflecting operating cash use and the reclassification of matured securities into cash.
Outlook, clinical developments and risks
- Management estimates existing cash, cash equivalents and marketable securities will fund planned development and operations into the second half of 2025. This estimate depends on assumptions that may prove incorrect; additional capital will be needed thereafter and is not assured. Management reported no substantial doubt about the company’s ability to continue as a going concern for at least 12 months from issuance of the financial statements.
- IMM-1-104 Phase 2a dosing began in March 2024. The company anticipates enrolling approximately 150 patients across five monotherapy and combination arms and plans to announce initial data from multiple arms in 2024.
- In March, the company reported positive topline Phase 1 results for IMM-1-104 based on data available as of February 20, 2024. Among 41 patients, reported tolerability included no grade 4 treatment-related adverse events and one grade 3 event; the company selected 320 mg once daily as its candidate Phase 2 dose. Reported tumor-lesion regressions were exploratory observations, not a Phase 1 clinical activity endpoint. These are interim company-reported results and may change as data mature and are verified.
- The FDA granted IMM-1-104 Fast Track designation for pancreatic ductal adenocarcinoma after one line of treatment. IMM-6-415 Phase 1 dosing began in March 2024; the company expects to provide initial pharmacokinetic, pharmacodynamic and safety data in 2024.
- Management expects expenses, particularly R&D, to increase as clinical programs advance. Key risks include clinical safety or efficacy setbacks, enrollment and trial delays, regulatory uncertainty, dependence on third-party manufacturers and CROs, and the need to raise additional capital. Further equity financing could dilute shareholders.
- The company noted a market-capitalization decline in March as a potential goodwill impairment indicator; no impairment was identified for the quarter. No material legal proceedings were reported. Disclosure controls were assessed as effective at the reasonable-assurance level.
Important facts for investors to verify
- Whether the interim IMM-1-104 safety, pharmacodynamic and tumor-response observations are confirmed in mature, independently reviewed data and in Phase 2a.
- Clinical enrollment, dose selection, combination-arm progress and timing of disclosed data for both candidates.
- Actual cash burn and whether the stated runway into the second half of 2025 remains achievable as trial spending increases.
- Future financing plans, including potential ATM or other equity issuance, and the resulting dilution; no ATM shares were sold in Q1 2024.
- Whether the March market-capitalization decline or other developments require future impairment testing or charges.